N2off stockholders approve merger with drug discovery company targeting resistant cancers including pancreatic and non-small cell lung cancer

Neve yarak, israel, sept. 25, 2025 (globe newswire) -- n2off, inc. (nasdaq: nito) (“n2off” and the “company”), a cleantech company investing in solar energy assets based on the rtb (ready to build) business model, announced today that a special meeting of stockholders held on september 25, 2025, its stockholders voted on and approved, among others, the proposed acquisition of mitocarex bio ltd. ("mitocarex"), a biotech company focused on drug discovery targeting cancer therapeutics, with a range of other potential diseases and disorders, through targeting the mitochondrial slc25 protein family.
NITO Ratings Summary
NITO Quant Ranking